Wire Stories
639VicTrack Rides With Juniper Networks on Network Refresh Journey to Fuel Business Growth
Juniper-powered solutions enable VicTrack to build on its wide transportation network to provide leading communications solutions to customers across its target verticals...
- 654
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials across eight types of cancer Featuring three...
- 902
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
– Durable Responses Observed in Second Cohort of Patients in Pivotal EV-201 Trial of PADCEV and in Initial First-Line Cohort of the...
- 662
Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Results of the Phase III AENEAS trial, to be presented at ASCO 2021, demonstrate better efficacy and improved tolerability, including less frequent...
- 655
KE Holdings Inc. Announces First Quarter 2021 Unaudited Financial Results
BEIJING–(BUSINESS WIRE)–KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE), a leading integrated online and offline platform for housing transactions and services,...
- 640
Digi Relocates Australian Headquarters to Milton to Bolster Exponential Growth and Opportunities
Newly renovated facility in Milton will drive collaboration, and engineering leadership to re-affirm market-leading position as employees return to office HOPKINS, Minn.–(BUSINESS...
- 839
Labcorp to Expand Bioanalytical Services With Integrated Laboratory in Singapore
New Laboratory Grows Asia-Pacific Operations BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp (NYSE: LH), a leading global life sciences company, today announced the expansion of its...
- 629
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
– OPTIC Trial Evaluating Response-Based Dosing Regimens of ICLUSIG for the Treatment of Resistant / Intolerant Chronic-Phase CML Demonstrates Durable, Clinically Meaningful...
- 578
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
? Mobocertinib, an Oral Targeted Therapy, Demonstrated a Median Overall Survival of 24 Months, and Responses were Observed across Diverse EGFR Exon20...
- 586
Sugarbud Announces Second Consecutive Positive EBITDA Result for Q1 2021, Filing of First Quarter Financial Results and Corporate Update
CALGARY, Alberta, May 19, 2021 (GLOBE NEWSWIRE) — Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.DB, SUGR.WR, SUGR.WS, SUGR.WT) (OTCQB: SBUDF) (“Sugarbud”) is...
